Multiple Sclerosis News

SAN DIEGO — Among individuals from the United Kingdom with multiple sclerosis, autologous hematopoietic stem cell transplantation led to significant relapse suppression up to 4 years, according to a speaker.

SAN DIEGO — Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis, according to research presented at AAN.

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 weeks compared with sham in patients aged 2 to 18 years with spinal muscular atrophy, data show.

Treatment with losmapimod resulted in no clear benefit compared with placebo in individuals with facioscapulohumeral muscular dystrophy at 48 weeks, according to research presented at the Muscular Dystrophy Association Clinical & Scientific Conference.

WEST PALM BEACH, Fla. — More than a century of scientific research has shed light on the neuroimmune interaction in multiple sclerosis, which will be key for the development of disease-specific therapies, according to Jack P. Antel, MD.

WEST PALM BEACH, Fla. — Two experts debated the issue of whether subtypes of multiple sclerosis exist, one from Europe and the other from the United States, during the final day of ACTRIMS.

WEST PALM BEACH, Fla. — Revisions made in 2024 to the McDonald criteria allowed for the diagnosis of multiple sclerosis in a small cohort of individuals with atypical presentation, according to a speaker at ACTRIMS.

WEST PALM BEACH, Fla. — Ocrelizumab significantly reduced the number and volume of cortical lesions associated with multiple sclerosis at 120 weeks, findings confirmed by data from a series of new imaging techniques and presented at ACTRIMS.

WEST PALM BEACH, Fla. — Large language model algorithms may be reliable for synthesizing large patient databases to more rapidly and accurately diagnose multiple sclerosis, according to a poster presented at ACTRIMS.